TYMP and gastric cancer: The TYMP-targeting drug TAS-102, a trifluridine-tipiracil hydrochloride mixture, is currently approved for treating advanced colorectal cancer and gastric cancer [49, 50] after at least two lines of chemotherapy [51–54].